Patent · US Active

Optimized anti-TL1A antibodies

US11440954B2 · kind B2 · utility

2Cited by

72References

20Claims

0Family size

Assignees

PROMETHEUS BIOSCIENCES, INC. · US
Cedars Sinai Medical Center · US

Inventors

Jeffry D. Watkins · Encinitas, US
Cindy T. Dickerson · Encinitas, US
J. Monty Watkins · Encinitas, US
Patricia McNeeley · San Diego, US
Janine Bilsborough · Simi Valley, US
Bradley Henkle · West Hollywood, US
Stephan R. Targan · Santa Monica, US

Key dates

Filing date	Apr 30, 2020
Grant date	Sep 13, 2022
Priority date	—
Expiry date	Aug 28, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.